Phosphate Therapeutics

Phosphate Therapeutics is focused on the development of mineral-derived hospital pharmaceuticals.

Phosphate Therapeutics, a UK-based independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals. The company intends to use the capital to complete the Phase 2 development of its phosphate binder (PT20) for the treatment of a late-stage renal disease suffer from systemic phosphate accumulation, hyperphosphataemia, whose global rights were acquired from the Medical Research Council.